Managing ocular toxicities in myeloma

January 14, 2021

Shaily Shah, MD, and Esen Karamursel Akpek, MD, discuss managing the potential ocular toxicities that can occur with belantamab mafodotin-blmf in patients with relapsed/refractory multiple myeloma, as well as the collaborative role between ophthalmologists and oncologists.


Related Content:

Video Series